Ethinylestradiol/levonorgestrel - Pfizer

Drug Profile

Ethinylestradiol/levonorgestrel - Pfizer

Alternative Names: Alesse; Alesse21; Alesse28; Levonorgestrel/ethinlyestradiol - Wyeth; Loette

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Androgen receptor modulators; Estrogen receptor agonists; Gonadotropin inhibitors; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Pregnancy

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 22 Jul 2002 A study has been added to the Women's Health therapeutic trials section
  • 27 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top